Name

L-VAM

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for L-VAM

Name

Alternate Names

Ametycine
Mito-Medac
Mitocin
Mitocin-C
MitoExtra
Mitomycin-C
Mitomycin-X
Mutamycin
Mutamycine

Abbreviations

MITC
Mito
MITO-C
MMC
MTC

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

26980
026980

Primary Site

Breast
Cervical cancer
Gastric cancer
Head and Neck (in combination with radiation therapy)
Non-small cell lung cancer (NSCLC)
Pancreatic cancer
Superficial bladder cancer

Histology

None

Remarks

FDA approved for treatmen of many cancers.

Coding

This drug should be coded

Name

Alternate Names

Abbott-43818
Carcinil
Eligard
Leuprolide
Leuprorelin
Lupron
Lupron Depot
Lupron TAP
TAP-144
Viadur

Abbreviations

None

Category

Hormones and hormonal mechanisms

Subcategory

Gonadotropin-releasing hormone agonist

NSC Number

377526

Primary Site

Prostate cancer
See remarks for other site information
Breast
Ovary

Histology

None

Remarks

December 2016 Update: Lupron as ovarian suppressor in pre-menopausal breast cancer has been approved by the FDA per NCI. Beginning with cases diagnosed 1/1/2017 forward, code as hormone therapy.

Lupron is a gonadotropin-releasing hormone analogue. FDA approved its use on prostate cancer and should be coded as hormone therapy.

FOR BREAST CASES DIAGNOSED 1/1/2017 FORWARD: Code as hormone treatment

FOR BREAST CASES DIAGNOSED PRIOR TO 1/1/2017:
The effectiveness of Lupron on patients with breast cancer was being studied in one clinical trial. This trial was looking at extended endocrine therapy for pre-menopausal women with breast cancer. This trial is looking at the drug combination of letrozole and leuprolide for women who have taken Tamoxifen for at least 4-5 years. This drug combination is used in the treatment for metastatic breast cancer and is sometimes used for treatment of early stage breast cancer. However, as of early December 2016 it has not been accepted as a standard of care treatment and had not yet received FDA approval for treatment of breast cancer. While it may not have received FDA approval, it can be used "off label" for other conditions. Lupron should be coded as "Other Therapy" until such time that it receives FDA approval.

Coding

Please see remarks for additional information

Name

Alternate Names

14-hydroxy-daunomycin
Adri-blastina (Italy)
Adriamycin
Adriamycin-TM
Caelyx
FT-106
Hydroxydaunomycin
Myocet
Pegylated Liposomal Doxorubicin Hcl
Rubex
S-DOX
Stealth(R) Liposomal Doxorubicin

Abbreviations

ADM
ADR
ADRI

Category

Chemotherapy

Subcategory

Antitumor antibiotic

NSC Number

123127

Primary Site

Bladder
breast
liver
multiple myeloma
ovarian
pancreatic
prostate cancer

Histology

None

Remarks

Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm's tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic

Coding

This drug should be coded

Name

Alternate Names

29060-LE
Alkaban
LE-29060
Velban
Velbe
Velsar
Vinblastine
Vinblastine sulfate

Abbreviations

VBL
VELB
VLB

Category

Chemotherapy

Subcategory

Plant alkaloid

NSC Number

049842
49842

Primary Site

None

Histology

None

Remarks

A cell cycle specific chemotherapeutic agent; vinca plant alkaloid; mitotic inhibitor. FDA approved uses in 3rd line breast cancer, choriocarcinoma, palliative in stages III and IV Hodgkin's lymphoma, Kaposi's sarcoma, mycosis fungoides, palliative in non-Hodgkin's histiocytic/lymphocytic lymphoma, and advanced testicular carcinoma.

Coding

This drug should be coded
Glossary